Potent anti-inflammatory activity of ursolic acid, a triterpenoid antioxidant, is mediated through suppression of NF-κB, AP-1 and NF-AT

PLoS One. 2012;7(2):e31318. doi: 10.1371/journal.pone.0031318. Epub 2012 Feb 20.

Abstract

Background: Ursolic acid (UA), a pentacyclic triterpenoid carboxylic acid, is the major component of many plants including apples, basil, cranberries, peppermint, rosemary, oregano and prunes and has been reported to possess antioxidant and anti-tumor properties. These properties of UA have been attributed to its ability to suppress NF-κB (nuclear factor kappa B) activation. Since NF-κB, in co-ordination with NF-AT (nuclear factor of activated T cells) and AP-1(activator protein-1), is known to regulate inflammatory genes, we hypothesized that UA might exhibit potent anti-inflammatory effects.

Methodology/principal findings: The anti-inflammatory effects of UA were assessed in activated T cells, B cells and macrophages. Effects of UA on ERK, JNK, NF-κB, AP-1 and NF-AT were studied to elucidate its mechanism of action. In vivo efficacy of UA was studied using mouse model of graft-versus-host disease. UA inhibited activation, proliferation and cytokine secretion in T cells, B cells and macrophages. UA inhibited mitogen-induced up-regulation of activation markers and co-stimulatory molecules in T and B cells. It inhibited mitogen-induced phosphorylation of ERK and JNK and suppressed the activation of immunoregulatory transcription factors NF-κB, NF-AT and AP-1 in lymphocytes. Treatment of cells with UA prior to allogenic transplantation significantly delayed induction of acute graft-versus-host disease in mice and also significantly reduced the serum levels of pro-inflammatory cytokines IL-6 and IFN-γ. UA treatment inhibited T cell activation even when added post-mitogenic stimulation demonstrating its therapeutic utility as an anti-inflammatory agent.

Conclusions/significance: The present study describes the detailed mechanism of anti-inflammatory activity of UA. Further, UA may find application in the treatment of inflammatory disorders.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Anti-Inflammatory Agents / pharmacology*
  • Antibodies, Monoclonal / pharmacology
  • Antioxidants / pharmacology*
  • B-Lymphocytes / cytology
  • B-Lymphocytes / drug effects
  • B-Lymphocytes / enzymology
  • B-Lymphocytes / metabolism
  • CD28 Antigens / immunology
  • CD3 Complex / immunology
  • CD4-Positive T-Lymphocytes / cytology
  • CD4-Positive T-Lymphocytes / drug effects
  • CD4-Positive T-Lymphocytes / enzymology
  • CD4-Positive T-Lymphocytes / metabolism
  • CD8-Positive T-Lymphocytes / cytology
  • CD8-Positive T-Lymphocytes / drug effects
  • CD8-Positive T-Lymphocytes / enzymology
  • CD8-Positive T-Lymphocytes / metabolism
  • Cell Proliferation / drug effects
  • Concanavalin A / pharmacology
  • Cytokines / metabolism
  • Graft vs Host Disease / immunology
  • Graft vs Host Disease / pathology
  • Lymphocyte Activation / drug effects
  • Lymphocyte Activation / genetics
  • Macrophages / cytology
  • Macrophages / drug effects
  • Macrophages / metabolism
  • Mice
  • Mitogen-Activated Protein Kinases / metabolism
  • Mitogens / pharmacology
  • NF-kappa B / metabolism*
  • NFATC Transcription Factors / metabolism*
  • Oxidation-Reduction / drug effects
  • Reactive Oxygen Species / metabolism
  • Transcription Factor AP-1 / metabolism*
  • Triterpenes / pharmacology*
  • Up-Regulation / drug effects
  • Ursolic Acid

Substances

  • Anti-Inflammatory Agents
  • Antibodies, Monoclonal
  • Antioxidants
  • CD28 Antigens
  • CD3 Complex
  • Cytokines
  • Mitogens
  • NF-kappa B
  • NFATC Transcription Factors
  • Reactive Oxygen Species
  • Transcription Factor AP-1
  • Triterpenes
  • Concanavalin A
  • Mitogen-Activated Protein Kinases